'Pluvicto ushers in new era for prostate cancer care, showing strong results even in elderly patients'
Patients with metastatic castration-resistant prostate cancer (mCRPC) are mainly elderly and face rapid disease progression, making current treatment options limited in extending survival and enhancing quality of life. In this context, radioligand therapy …